Anti-CGRP MAbs set to take 41.7% of $12 billion global migraine market by 2030, says analyst

Ever since their launch in 2018, anti-calcitonin gene-related peptide monoclonal antibodies (CGRP) monoclonal antibodies (MAbs) have been stealing market share in the migraine treatment space from traditional oral preventative products such as generic anti-depressants, anti-epileptic agents, and beta blockers.

According to data and analytics company GlobalData, anti-CGRP MAbs have been shown to effectively reduce the number of days per month that a patient suffers a migraine, while also being well tolerated by patients and offering a convenient dosing schedule.

The company’s latest report,  ‘Migraine Drug Market Size, Share & Trends Analysis and Forecast by Strategic Competitor Assessment, Market Characterization, Unmet Needs, Clinical Trial Mapping and Implications 2020 – 2030’, reveals that anti-CGRP MAbs’ share of the migraine market is set to rise at a 17.6% compound annual growth rate (CAGR) to reach $5 billion in 2030. Further, the increased uptake of anti-CGRPs MAbs, and gepants - a second drug type targeting CGRP - will drive the migraine market to grow from $4.7 billion in 2020 to $12 billion in 2030 across the seven major markets (7MM; USA, France, Germany, Italy, Spain, the UK, and Japan) at a compound annual growth rate (CAGR) of 9.9%.